An open label, sequential non-randomised pharmacokinetics study comparing lopinavir plasma exposure when given as lopinavir superboosted with ritonavir (1:1 ratio) in the presence of rifampicin or lopinavir boosted with ritonavir (4:1 ratio) in the absence of rifampicin in HIV and TB co-infected children in South Africa

Trial Profile

An open label, sequential non-randomised pharmacokinetics study comparing lopinavir plasma exposure when given as lopinavir superboosted with ritonavir (1:1 ratio) in the presence of rifampicin or lopinavir boosted with ritonavir (4:1 ratio) in the absence of rifampicin in HIV and TB co-infected children in South Africa

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Abacavir; Antiretrovirals; Ethambutol; Isoniazid; Nucleoside reverse transcriptase inhibitors; Pyrazinamide; Rifampicin
  • Indications HIV-1 infections; Tuberculosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 21 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 03 May 2013 Status changed from not yet recruiting to recruiting as reported by Pan-African Clinical Trials Registry.
    • 19 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top